Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.
emeis Société anonyme stock reacts to recent performance data
emeis Société anonyme (ENXTPA:EMEIS) has drawn fresh attention after recent performance data highlighted mixed signals, with the stock higher over the past month while longer term returns remain sharply weaker for investors.
See our latest analysis for emeis Société anonyme.
The recent 4.00% 1-day and 14.49% 30-day share price returns, with the stock now at €15.33, sit against a mixed backdrop of a 4.86% year to date share price gain, a 48.12% 1-year total shareholder return and much weaker 3 and 5 year total shareholder returns. This suggests that short term momentum has improved while long term holders have faced heavy value erosion.
If this kind of rebound has you thinking about where else capital might work harder, it could be a good moment to broaden your watchlist with the 100 top founder-led companies
With the stock trading at €15.33, sitting above the analyst price target but at a steep discount to one intrinsic value estimate, you have to ask: is emeis Société anonyme undervalued, or is the market already pricing in future growth?
Most Popular Narrative: 15.4% Overvalued
Against the current share price of €15.33, the most followed narrative anchors fair value at €13.28, using a discount rate of 9.76% and a detailed earnings and cash flow path.
Demographic driven growth in demand for long term care capacity across Europe, combined with limited public sector supply, positions emeis to selectively ramp up existing sites and pursue new asset light developments, in line with a 4 to 5 percent annual revenue growth target and an ambition for double digit EBITDA CAGR.
Want to see how modest revenue assumptions, a margin rebuild and a premium earnings multiple are stitched together into that fair value? The full narrative sets out the earnings bridge, the valuation framework and the tension between growth hopes and today’s loss making base.
Result: Fair Value of €13.28 (OVERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, these expectations sit on shaky ground if occupancy stalls or regulatory pressure drives higher staffing costs and tighter pricing, which could squeeze margins and delay any earnings recovery.
Find out about the key risks to this emeis Société anonyme narrative.
Another View: Multiples Tell a Different Story
While the narrative driven fair value points to emeis Société anonyme being 15.4% overvalued at €13.28 versus the €15.33 share price, the P/S based view is very different, with the stock at 0.4x sales compared with a fair ratio of 0.5x and 0.7x for both peers and the wider European Healthcare industry.
That gap suggests the market is pricing in more business risk and execution uncertainty than the sector average, so the key question is whether you think those concerns are justified or overly cautious.
See what the numbers say about this price — find out in our valuation breakdown.
ENXTPA:EMEIS P/S Ratio as at May 2026 Next Steps
If this mix of cautious sentiment and potential upside has you curious, do not wait too long to review the numbers yourself. Carefully weigh the potential upside against the risks in the 4 key rewards
Looking for more investment ideas?
If you stop with just one stock, you risk missing out on other opportunities, so put a few minutes aside to scan wider and test fresh ideas.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include EMEIS.PA.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com